BioLineRx Ltd. is an Israeli biopharmaceutical company focused on oncology and rare diseases. Its first approved product is APHEXDA (motixafortide), an FDA-approved peptide for hematopoietic stem cell mobilization in multiple myeloma patients. The company has out-licensed motixafortide rights to partners in Asia and globally, and in September 2025 entered a collaboration with Hemispherian to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other solid tumors.
432 total filings indexed. 432 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001498403 |
| Ticker | BLRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | L3 |
| Website | https://www.biolinerx.com |
| Listed | 2011-07-25 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BLRX (~200 tokens, structured JSON with cryptographic provenance)